Article
Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.
Hepatology (Baltimore, Md.) - 1 Jul 2003
Westland Christopher E, Yang Huiling, Delaney William E, Gibbs Craig S, Miller Michael D, Wulfsohn Michael, Fry John, Brosgart Carol L, Xiong Shelly
Abstract excerpt
Seven hundred nucleoside treatment-naive patients were enrolled in two phase 3 trials of adefovir dipivoxil (ADV) for the treatment of chronic hepatitis B. To monitor for the emergence of potential adefovir resistance mutations over the first 48 weeks, all intent-to-treat patients (467 ADV-treated and 228 placebo patients) were included in a prospectively defined, treatment-blinded, virology substudy. The study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.